Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Gastroenterology. 2020 May 4;159(2):562–574. doi: 10.1053/j.gastro.2020.04.057

Figure 5.

Figure 5.

Additional validation of performance of the miRNA signature for predicting residual nodal involvement following neoadjuvant therapy in EUS-FNA biopsy specimens.

(A) A ROC curve of the 6-miRNA signature in additional validation cohort (pre-NAT EUS-FNA biopsies; ypN positive = 9, ypN negative = 53, AUC = 0.78). (B) Risk score distribution plots in an additional validation cohort. (C) The distribution of risk scores according to ypN status (P < 0.01, Mann Whitney test. (D) Forest plots with odds ratio for clinicopathological variables and risk scores in multivariate logistic regression analysis of ypN status in an additional validation cohort.